WisdomTree BioRevolution Fund WDNA

Medalist Rating as of | See WisdomTree Investment Hub

Morningstar’s Analysis WDNA

Will WDNA outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

WisdomTree BioRevolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings WDNA

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 30.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

5.65 146,875
Healthcare

Eli Lilly and Co

4.17 108,478
Healthcare

Moderna Inc

3.82 99,221
Healthcare

Johnson & Johnson

3.07 79,961
Healthcare

United Therapeutics Corp

2.53 65,887
Healthcare

Immunome Inc Ordinary Shares

2.47 64,282
Healthcare

Natera Inc

2.42 62,962
Healthcare

Darling Ingredients Inc

2.33 60,513
Consumer Defensive

10x Genomics Inc Ordinary Shares - Class A

2.15 55,900
Healthcare

Tempus AI Inc Class A common stock

2.15 55,881
Healthcare

Sponsor Center